MAFA-AS1: MAFA-AS1 is a long non-coding RNA (lncRNA) that has not been previously reported to be related to hepatocellular carcinoma (HCC) biology, and its functions and mechanisms in HCC need further investigation [PMC7377850]. A study found that MAFA-AS1 is correlated with hsa-miR-210, an oncogenic miRNA in many cancers [PMC8798454]. MAFA-AS1 has been shown to distinguish early-stage HCC patients from advanced stage patients and is associated with worse outcomes in HCC [PMC8798454]. It interacts with RNA-binding proteins SRSF1 and SRSF9, potentially affecting DNA replication and the cell cycle [PMC8798454]. Additionally, MAFA-AS1 interacts with miR210 and affects DNA replication and the cell cycle through GO and KEGG analyses [PMC8798454]. MAFA-AS1 has a stable secondary structure [PMC8798454]. It is not believed to affect neighboring genes through spatial interactions but may regulate other oncogenes or tumor suppressors in HCC [PMC8798454]. Furthermore, MAFA-AS1 has been identified as a prognostic marker for HCC, as its high expression predicts poor overall survival (OS) and disease-free survival (DFS) rates in patients with HCC [PMC8798454]. In other cancer types such as diffuse large B-cell lymphoma (DLBCL), MAFA-AS1 has also been associated with poor prognosis [PMC7298280][PMC8668967][PMC9641000][PMC9187470].